Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29268982 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6USP30UCHL1POLB | |
| SCHEMBL29268985 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6USP30UCHL1POLB | |
| SCHEMBL29268997 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL29268998 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL30474006 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL25675708 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL25675712 | 0.91 | FAAH (0.34) | HDAC1HDAC6USP30RORC | |
| SCHEMBL30474019 | 0.91 | FAAH (0.34) | HDAC1HDAC6USP30RORC | |
| SCHEMBL24073258 | 0.90 | HDAC1 (0.44) | HDAC1HDAC6USP30RORC | |
| SCHEMBL29269034 | 0.90 | HDAC1 (0.34) | HDAC1HDAC6USP30RORCGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | HDAC1 560/4885HDAC6 764/4885USP30 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.